Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease

被引：28
|
作者：
Restellini, Sophie [1 ,2 ]
Afif, Waqqas [1 ]
机构：
[1] McGill Univ, Hlth Ctr, Div Gastroenterol, Montreal, PQ H3G 1A4, Canada
[2] Genevas Univ Hosp, Div Gastroenterol & Hepatol, CH-1205 Geneva, Switzerland
来源：
JOURNAL OF CLINICAL MEDICINE | 2021年 / 10卷 / 06期
关键词：
therapeutic drug monitoring; biologic; ustekinumab; vedolizumab; tofacitinib; ACTIVE ULCERATIVE-COLITIS; JANUS KINASE INHIBITOR; MAINTENANCE THERAPY; CROHNS-DISEASE; INDUCTION THERAPY; TROUGH CONCENTRATIONS; MONOCLONAL-ANTIBODY; DOUBLE-BLIND; ASSOCIATION; PHARMACOKINETICS;
D O I：
10.3390/jcm10061242
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The goal of therapeutic drug monitoring (TDM) is to optimize anti-TNF (tumor necrosis factor) biologic treatment in patients with inflammatory bowel disease (IBD). Although commercial assays are readily available for both ustekinumab and vedolizumab, the use of TDM with these newer biologic medications is at its infancy. The clinical utility of TDM with non-anti-TNF mechanisms of action is not clear. This review summarizes the latest available data on the pharmacokinetics of newer biologic and oral small molecules and highlights the threshold concentrations that have been associated with improved outcomes in IBD patients.
引用
收藏
页码：1 / 16
页数：15
相关论文
共 50 条
  • [41] The role of ustekinumab and vedolizumab in management of extra intestinal manifestations in inflammatory bowel disease
    Katsanos, Konstantinos H.
    Fousekis, Fotios S.
    Armuzzi, Alessandro
    [J]. DIGESTIVE AND LIVER DISEASE, 2023, 55 (02) : 149 - 150
  • [42] The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
    Choi, Myeong Geun
    Ye, Byong Duk
    Yang, Suk-Kyun
    Shim, Tae Sun
    Jo, Kyung-Wook
    Park, Sang Hyoung
    [J]. JOURNAL OF KOREAN MEDICAL SCIENCE, 2022, 37 (14)
  • [43] A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases
    Shim, Hang Hock
    Chan, Pak Wo
    Chuah, Sai Wei
    Schwender, Brian J.
    Kong, San Choon
    Ling, Khoon Lin
    [J]. JGH OPEN, 2018, 2 (05): : 223 - 234
  • [44] Ustekinumab and vedolizumab influence on cardiovascular risk factors in patients with Inflammatory Bowel Disease
    Amiama Roig, C.
    Suarez Ferrer, C.
    Poza Cordon, J.
    Rueda Garcia, J. L.
    Sanchez Azofra, M.
    Martin Arranz, E.
    Gonzalez Diaz, I.
    Amor Costa, C.
    Garcia Ramirez, L.
    Martin Arranz, M. D.
    [J]. JOURNAL OF CROHNS & COLITIS, 2021, 15 : S462 - S463
  • [45] Outcomes Combining Vedolizumab With Other Biologics or With Tofacitinib to Treat Inflammatory Bowel Disease
    Llano, Ernesto M.
    Shrestha, Shreeju
    Boktor, Moheb
    Fudman, David I.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S407 - S407
  • [46] Safety and Efficacy of Ustekinumab and Vedolizumab Among Older Adults With Inflammatory Bowel Disease
    Sachar, Moniyka
    Fernandez, Cristina
    Beaty, William
    Rojanasopondist, Pakdee
    Delau, Olivia
    Li, Alice
    Murphy, Megan
    Axelrad, Jordan
    Hong, Simon J.
    Holmer, Ariela
    Chang, Shannon
    Hudesman, David
    Katz, Seymour
    Malter, Lisa
    Faye, Adam S.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S866 - S867
  • [47] Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease- a retrospective study
    Livne-Margolin, Moran
    Ling, Daniel
    Attia-Konyo, Shani
    Abitbol, Chaya Mushka
    Haj-Natour, Ola
    Ungar, Bella
    Ben-Horin, Shomron
    Kopylov, Uri
    [J]. DIGESTIVE AND LIVER DISEASE, 2023, 55 (02) : 223 - 229
  • [48] Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring
    Wiken, Thea H.
    Hoivik, Marte L.
    Buer, Lydia
    Warren, David J.
    Bolstad, Nils
    Moum, Bjorn A.
    Anisdahl, Karoline
    Smastuen, Milada C.
    Medhus, Asle W.
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2023, : 863 - 873
  • [49] Therapeutic drug monitoring (TDM) in patients with inflammatory bowel disease (IBD) as an example of the development of theranostics - Personalized precision medicine
    Podstawka, I.
    Skorupa, E.
    Ochocinska, A. M.
    Wlazlo, M.
    Meglicka, M.
    [J]. CLINICA CHIMICA ACTA, 2024, 558
  • [50] Therapeutic Drug Monitoring of Adalimumab in Patients With Inflammatory Bowel Disease
    El-Matary, Wael
    [J]. CROHNS & COLITIS 360, 2019, 1 (03)
12345